NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

735.22 -10.47 (-1.40%)
As of 2:08 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. David A. Ricks Chairman, CEO & President 6.29M -- 1968
Ms. Anat Ashkenazi Executive VP & CFO 2.96M -- 1973
Dr. Daniel M. Skovronsky M.D., Ph.D. EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology 3.82M -- 1974
Ms. Anat Hakim J.D. Executive VP, General Counsel & Secretary 2.81M -- 1969
Mr. Jacob S. Van Naarden Executive VP & President of Loxo 2.38M -- 1985
Mr. Donald A. Zakrowski Senior VP of Finance & Chief Accounting Officer -- -- --
Mr. Diogo Rau EVP & Chief Information and Digital Officer 1.06M -- 1975
Mr. Alonzo Weems EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer -- -- 1972
Mr. Eric Dozier Executive Vice President of Human Resources & Diversity -- -- 1968
Mr. Jeffrey N. Simmons Senior VP & President of Elanco Animal Health 1.73M -- 1967

Eli Lilly and Company

Lilly Corporate Center
Indianapolis, IN 46285
United States
317 276 2000 https://www.lilly.com
Sector: 
Healthcare
Full Time Employees: 
43,000

Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Corporate Governance

Eli Lilly and Company’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 9; Compensation: 1.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Mar 22, 2024
    DEFA14A: Proxy Statements
    See Full Filing
  • Mar 08, 2024
    PRE 14A: Proxy Statements
    See Full Filing
  • Mar 08, 2024
    Dividend Date
  • Feb 21, 2024
    10-K: Periodic Financial Reports
    See Full Filing
  • Feb 14, 2024
    Ex-Dividend Date

Upcoming Events

Apr 30, 2024
Eli Lilly and Company Earnings Call

Related Tickers

PFE Pfizer Inc.
26.28
-0.17%
 
JNJ Johnson & Johnson
148.52
-0.70%
 
ABBV AbbVie Inc.
168.29
-0.74%
 
MRK Merck & Co., Inc.
127.30
+0.33%
 
AMGN Amgen Inc.
274.77
+0.45%
 
BMY Bristol-Myers Squibb Company
48.98
-0.02%
 
GILD Gilead Sciences, Inc.
66.96
-0.11%
 
NVS Novartis AG
98.15
+0.89%
 
BIIB Biogen Inc.
200.01
+3.54%
 
AZN AstraZeneca PLC
71.11
+0.36%